Navigation Links
Repligen Reports Second Quarter Fiscal Year 2011 Financial Results
Date:11/2/2010

000 compared to $13,116,000 for the same period in fiscal year 2010.  Net income for the six-month period ended September 30, 2010 was $1,611,000 or $0.05 per diluted share compared to a net loss of $2,086,000 or $0.07 per diluted share for the same period in fiscal year 2010.

Corporate UpdateRG1068 for Imaging of the Pancreas We are currently analyzing the radiographic images from our Phase 3 study of RG1068, synthetic human secretin.  The goal of the study is to evaluate the sensitivity and specificity of RG1068 in combination with MRI to improve the detection of structural abnormalities of the pancreatic ducts relative to MRI alone.  Detailed visual assessment of the pancreatic ducts is important in the evaluation of pancreatic duct abnormalities which may result in the diagnosis of diseases such as acute and chronic pancreatitis.  Because RG1068-MRI elucidates both normal and abnormal anatomy, it may improve patient triage and pre-surgical planning and could aid in avoiding unnecessary procedures such as endoscopy which is associated with serious adverse events.  Data from the Phase 3 study indicates that the use of RG1068-MRI to avoid unnecessary endoscopy would result in saving an average of one day of hospitalization per patient.

The analysis of the Phase 3 image data is a "re-read" which was agreed to by the Food and Drug Administration and European Medicines Agency based on the determination that the original analysis was flawed and therefore inconclusive due to deficiencies in performance by the contract research organization overseeing the analysis.  We have selected a new contract research organization, and they are currently building the database for the new readers to conduct their analysis.  We expect to report top-line results in the first quarter of 2011 which, if positive, may support product registration.  There are more than 300,000 MRIs conducted in the U.S. and Europe each year that coul
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
4. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
7. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
8. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
9. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
10. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
11. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... Mass. , Jan. 22, 2015   GenoSpace , a ... of tools to enable the broad use of genomic, imaging ... announced the appointment of Michelle Munson , CEO of ... director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... N.J., Nov. 13 Soligenix, Inc., (Soligenix or ... as DOR BioPharma, Inc., a late-stage biotechnology company, ... quarter of 2009. , Highlights and ... enrollment in its confirmatory Phase 3 randomized, double-blind, ...
... ... System that addresses common problems associated with purification of recombinant proteins by enabling ... , ... Madison, WI (PRWEB) November 12, 2009 -- The recently released Promega HaloTag® Protein ...
... Exchange Symbol: MS , EDMONTON, Nov. 12 /PRNewswire-FirstCall/ - ... operational results for the three and nine months ended ... license and collaboration agreement between BioMS Medical and Eli ... with the effect that all commercial rights to dirucotide ...
Cached Biology Technology:Soligenix Reports Third Quarter 2009 Financial Results 2Soligenix Reports Third Quarter 2009 Financial Results 3Soligenix Reports Third Quarter 2009 Financial Results 4Soligenix Reports Third Quarter 2009 Financial Results 5Promega HaloTag Protein Purification System Makes it Easier to Purify Difficult-to-Express Proteins 2BioMS Medical Announces Third Quarter 2009 Results 2BioMS Medical Announces Third Quarter 2009 Results 3BioMS Medical Announces Third Quarter 2009 Results 4BioMS Medical Announces Third Quarter 2009 Results 5BioMS Medical Announces Third Quarter 2009 Results 6BioMS Medical Announces Third Quarter 2009 Results 7BioMS Medical Announces Third Quarter 2009 Results 8
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... available in Spanish . Studies by ... presence of Escherichia coli pathogens in surface waters ... in underwater sediments. Most E. coli strains ... water quality managers to estimate fecal contamination. These findings, ...
... of years ago, humans discovered flammable gas could be produced ... anaerobic digestion. Today, EU laws are pushing governments to use ... to enrich soil or biogas for energy. Our environment would ... dumped in diminishing landfill sites. However, while the scientific ...
... have filled an important gap in the study of tunicate ... gelatinous, free-swimming types of tunicates. Their study was featured on ... of Plankton Research . Tunicates are a phylum of ... covering called a tunic, from which the name derives. ...
Cached Biology News:E. coli can survive in streambed sediments for months 2Time to make more out of waste 2Time to make more out of waste 3Woods Hole Oceanographic Institution study sheds light on tunicate evolution 2
... Immunogen: Recombinant human IDO ... for the ~44 kDa human ... (positive control: IFN-Gamma-stimmulated Human peripheral ... homology reactivity with mouse and ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
... Biochain's plant total protein ... for rapidly screening tissue specific ... Human placenta total protein is ... an interblot control for comparison ...
Biology Products: